Context
Majorelle is a French specialty pharma company focused on prescription and OTC products in women’s health, urology and family health. Notably, Majorelle has developed the most relevant and dynamic women’s health product range in the French market.
In less than a decade, founders Mehdi and Guillaume el Glaoui have built Majorelle into a unique fully-fledged specialty pharmaceutical company that commands leadership positions in its markets. The company employs 65 people and has experienced over 20% annual revenue and EBITDA growth in recent years.
EW Healthcare Partners is a global healthcare investment firm with close to USD 4bn raised since inception and seeking to make growth equity investments in fast growing commercial-stage healthcare companies.
Majorelle and EW Healthcare Partners have joined forces to grow into a pan-European specialty pharma company focusing on women’s health, urology and family health.
About Majorelle
Laboratoires Majorelle was founded in 2012 by Mehdi El Glaoui with the ambition to become the first pharmaceutical company with a responsible and citizen-centred approach dedicated to the resolution of public health concerns.
Today, it is a fully-fledged specialty pharmaceutical company developing and commercializing innovative solutions in women's health and urology. Laboratoires Majorelle is an established leader in the French oral contraceptives market with the Opti® range and has also dominant positions in urinary incontinence and erectile dysfunction treatment with KEAT® and Vitaros®.
Headquartered in Paris, Majorelle currently employs 65 people and is a long-term partner to more than 30,000 healthcare professionals in France, including gynaecologists, urologists and pharmacists.
About EW Healthcare Partners
With close to USD 4 billion raised since inception, EW Healthcare Partners is one of the largest and oldest private healthcare investment firms and seeks to make growth equity investments in fast growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the United States and in Europe.
Since its founding in 1985, EW Healthcare Partners has maintained its singular commitment to the healthcare industry and has been a long-term investor in over 150 healthcare companies, ranging across sectors, stages and geographies.
The team comprises over 20 senior investment professionals with offices in New York, Houston and London.
Deal Team
Should you want to know more about this transaction, you can contact one of the team members above
Bryan, Garnier & Co acts as Sole Financial Advisor to the shareholders of Laboratoires Majorelle on the sale of a majority stake to EW Healthcare Partners
Bryan, Garnier & Co led a highly competitive process involving French and international financial sponsors and advised Laboratoires Majorelle and its shareholders to select the best partner to support its growth and European expansion.
We initially assisted our client to define a precise framework for this transaction and then recommended a strategy to achieve it. As a result of absolute commitment of its team and a demanding process management, Bryan Garnier & Co delivered on all objectives.
This marks another successful transaction in pharmaceuticals and follows other notable deals recently advised by our team, including the acquisition of Gibaud by Innothera and the purchase of Laboratoires Iprad by Biocodex.
Share